ReviewFrontiers in bioengineering and biotechnology2026
Engineering biopolymer-based nanocarriers for cancer drug delivery: a system-level comparison of chitosan, hemicellulose, and lignin platforms with focus on tumor targeting, biodegradation, and immune modulation.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of biopolymer-based nanocarriers offers a transformative approach to cancer therapy, particularly in enhancing the efficacy and precision of chemotherapeutic agents such as 5-fluorouracil (5-FU), a widely used chemotherapeutic agent with limited tumor selectivity and rapid metabolic degradation. Among the vast array of natural polymers, chitosan, hemicellulose, and lignin, abundant, biodegradable, and derived from food and agricultural sources, have gained considerable attention as smart delivery vehicles. This review focuses on 5-FU as a clinically important but pharmacokinetically limited drug, and explores how polymer-based nanocarriers can overcome these challenges. We critically examine their biocompatibility, controlled release profiles, cellular uptake, and tumor-targeting mechanisms, along with their ability to overcome multidrug resistance and reduce systemic toxicity. Furthermore, we highlight recent advances in green synthesis techniques, surface engineering for active targeting, and synergistic applications with other bioactives or stimuli-responsive elements. By integrating insights from food science, nanotechnology, and oncology, this review underscores the promising role of chitosan, hemicellulose, and lignin nanoparticles in reshaping the landscape of cancer nanotherapeutics and paves the way for their translational potential in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.